Altacor and Proximagen have signed a collaborative research and development agreement for Proximagen's 5HT2c program in glaucoma, according to an Altacor news release.
Altacor will undertake the research and development of PRX00933, the lead compound from Proximagen's 5HT2c program. Altacor also gets an option for exclusive global rights to ophthalmic indications, but Proximagen will retain all rights outside of ophthalmology.
Proximagen acquired the program as part of the purchase of Cambridge Biotechnology Limited by Proximagen from Swedish Orphan Biovitrum. The purchase included the lead compound PRX00933, which has the potential to treat obesity, diabetes, epilepsy, urinary incontinence, and psychiatric and ophthalmology disorders.
Related Articles on Ophthalmology:
FDA Approves Eylea for Treatment of Age-related Macular Degeneration
10 Recent Findings on Ophthalmology
Surgery Devices, Minimally Invasive Procedures to Drive the Ophthalmic Surgery Market
Altacor will undertake the research and development of PRX00933, the lead compound from Proximagen's 5HT2c program. Altacor also gets an option for exclusive global rights to ophthalmic indications, but Proximagen will retain all rights outside of ophthalmology.
Proximagen acquired the program as part of the purchase of Cambridge Biotechnology Limited by Proximagen from Swedish Orphan Biovitrum. The purchase included the lead compound PRX00933, which has the potential to treat obesity, diabetes, epilepsy, urinary incontinence, and psychiatric and ophthalmology disorders.
Related Articles on Ophthalmology:
FDA Approves Eylea for Treatment of Age-related Macular Degeneration
10 Recent Findings on Ophthalmology
Surgery Devices, Minimally Invasive Procedures to Drive the Ophthalmic Surgery Market